Demonstration Formulary
3 Respiratory system
03-07 Mucolytics
| Carbocisteine |
|
Formulary
|
Prescribe as 375 mg caps. Avoid prescribing 750 mg caps
|
|
| Acetylcysteine oral presentations |
|
Formulary
|
|
|
|
| Acetylcysteine effervescent tablet Aceteff® |
|
Formulary
|
Acetylcysteine SF effervescent tabs most cost effective |
|
|
| Ivacaftor Kalydeco® |
|
Formulary
|
In line with NICE |
 Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations) |
|
| Lumacaftor with ivacaftor Orkambi® |
|
Formulary
|
In line with NICE |
|
NICE TA398: Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
|
|
| Mannitol Bronchitol® |
|
Restricted
|
Hospital only |
|
TA266: Mannitol dry powder for inhalation for treating cystic fibrosis |
|
Links
BCICB Asthma Treatment Guidelines - Adolescents 12-17 years old - BCICB Asthma Treatment Guidelines - Adults 18+
- BCICB Asthma Treatment Guidelines For Children Under 12
- BCICB COPD Inhaler Treatment Guidelines
- BCICB Difficult Asthma Referral Pathway - Adults 18+
- Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations)
- COVID-19: information for the respiratory community
- Greener Inhaler Guide Switching Information
- How to improve respiratory control in asthma and COPD
- NICE CG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
- NICE TA138: Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over
- NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation (TA266)
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA398: Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
- TA266: Mannitol dry powder for inhalation for treating cystic fibrosis